Board of Directors
David Hallal
Chairman of the Board of Directors, Scholar Rock®
Former Chief Executive Officer, Alexion Pharmaceuticals

Mr. Hallal has served as our Chairman since July 2017 and has nearly 30 years of experience building and leading organizations to develop and commercialize therapies for patients with severe and life-threatening conditions, including rare diseases. Most recently, Mr. Hallal spent more than ten years at Alexion Pharmaceuticals, Inc. in executive positions and played a central role in transforming the company from the pre-commercial stage in 2006 to greater than $3 billion in annual revenues by 2016. As the Chief Executive Officer of Alexion, Mr. Hallal transitioned the company from a single-product to a multi-product enterprise, including his most recent product development milestones of the highly successful launch of Strensiq® and the rapid advancement of Alexion’s highest value pipeline candidates form a preclinical stage to registration trials in multiple diseases in just 18 months. Prior to his appointment as CEO, Mr. Hallal served as Alexion’s Chief Operating Officer and then Chief Commercial Officer, where he built the company’s commercial infrastructure and a 50-country operating platform which launched Soliris® for two ultra-rare diseases, Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome, resulting in the most successful commercialization of an ultra-orphan drug in the biotechnology industry. Prior to Alexion, Mr. Hallal held commercial leadership positions at biopharmaceutical companies where he launched and expanded the adoption of numerous first-in-class and blockbuster products in hematology, oncology, nephrology, immunology and ophthalmology. At OSI Eyetech, he was Vice President of Sales where he led the U.S. launch of Macugen®, a first-in-class anti-VEGF therapy for the treatment of age-related macular degeneration. At Biogen, he led the immunology sales team, where he built the sales organization to launch Amevive®, a first-in-class biologic for psoriasis. For more than ten years starting in 1992, Mr. Hallal held various leadership roles at Amgen focused on the major oncology and hematology products Epogen®, Neupogen®, Neulasta® and Aranesp®. Mr. Hallal holds a BA in psychology from the University of New Hampshire.

Kristina Burow
Managing Director, ARCH Venture Partners
Kristina Burow is a Managing Director with ARCH Venture Partners and is focused on the creation and development of biotechnology, pharmaceutical and agbiotechnology companies. Since joining ARCH in 2002 Ms. Burow has played a significant role in the creation and development of a number of companies. Ms. Burow is also a Director of Vividion Therapeutics, Lycera, BlackThorn Therapeutics, Sienna Biopharmaceuticals, Metacrine, Unity Biotechnology, AgBiome, AgTech Accelerator and Vir Biotechnology. She previously was a co-founder and Director of Receptos (RCPT – acquired by Celgene). Ms. Burow has participated in a number of other ARCH portfolio companies including Siluria Technologies, Kythera (KYTH – acquired by Allergan), Ikaria (acquired by Madison Dearborn) and was a co-founder and board member of Sapphire Energy. Prior to joining ARCH Ms. Burow was an Associate with the Novartis BioVenture Fund in San Diego. As an early employee at the Genomics Institute of the Novartis Research Foundation (GNF), she directed Chemistry Operations and was active in Business Development where she helped create numerous companies as spin-outs from GNF. Ms. Burow holds a M.B.A. from the University of Chicago, a M.A. in Chemistry from Columbia University and a B.S. in Chemistry from the University of California, Berkeley.
Jeffrey S. Flier, MD
Higginson Professor of Physiology and Medicine and Harvard University Distinguished Service Professor
Former Dean of Harvard Medical School
Dr. Flier is the Higginson Professor of Physiology and Medicine and Harvard University Distinguished Service Professor, and was most recently the twenty-first Dean of the Faculty of Medicine at Harvard University. Dr. Flier received his BS from City College of New York, and MD from Mount Sinai School of Medicine with highest academic honors. Following residency training at Mount Sinai Hospital, Dr. Flier was a clinical associate at the NIH and then joined the faculty of medicine at Harvard Medical School, serving as chief of the diabetes unit and endocrine division at Beth Israel Hospital. Dr. Flier was subsequently named Chief Academic Officer of Beth Israel Deaconess, and served as Harvard Medical School Faculty Dean for Academic Programs. An elected member of the Institute of Medicine and a fellow of the American Academy of Arts and Sciences, his many honors include the Eli Lilly Award of the American Diabetes Association, and the Berson Lecture of the American Physiological Society. He was the recipient of the 2005 Banting Medal from the American Diabetes Association, its highest scientific honor.
Michael Gilman, PhD
CEO, Arrakis Therapeutics
CEO, Obsidian Therapeutics
Dr. Gilman is a scientist, general manager, biotech executive, and serial entrepreneur. He is currently Chair and CEO for Arrakis Therapeutics and CEO and Director for Obsidian Therapeutics. He also serves on the Board of Directors of X4 Pharmaceuticals and the SAB of FutuRx, an Israeli biotech accelerator. Previously, Dr. Gilman was Founder and CEO of Padlock Therapeutics, a venture-funded company focused on autoimmune disease, acquired by Bristol-Myers Squibb in 2016. Prior to Padlock, Dr. Gilman served as Senior Vice President, Early-Stage Pipeline, at Biogen Idec, with responsibility for managing the company’s development programs through clinical proof-of-concept. He joined Biogen Idec in March 2012 following its acquisition of Stromedix, a venture-backed company focused on fibrosis and organ failure, where he was Founder and CEO. Prior to founding Stromedix in 2006, Dr. Gilman served as EVP, Research at Biogen Idec, with responsibility for the company’s discovery research activities in Cambridge and San Diego. From 1994 to 1999, Dr. Gilman was at ARIAD Pharmaceuticals, where he was EVP and CSO. From 1986 to 1994, Dr. Gilman was on the scientific staff of Cold Spring Harbor Laboratory in New York, where his research focused on mechanisms of signal transduction and gene regulation. Dr. Gilman was a postdoctoral fellow with Dr. Robert Weinberg at the Whitehead Institute. He holds a Ph.D. in Biochemistry from University of California, Berkeley, and a S.B. in Life Sciences from Massachusetts Institute of Technology.
Nagesh K. Mahanthappa, PhD, MBA
CEO & President, Scholar Rock®
Dr. Mahanthappa is a biotechnology entrepreneur with 20 years of industry experience in roles spanning discovery research through early clinical development, as well as operations and strategy. Prior to Scholar Rock, Dr. Mahanthappa was a founding employee and VP, Corporate Development at Avila Therapeutics, Inc. (acquired by Celgene Corporation in 2012). Avila discovered and developed novel covalent drugs for the treatment of cancer, autoimmune, and viral diseases. He was previously a founding employee of Alnylam Pharmaceuticals, the first biotech established to discover RNA interference therapeutics and rose to VP, Scientific & Strategic Development. Earlier professional roles include business development at Vertex Pharmaceuticals, and discovery research at Ontogeny (now Curis, Inc.) and Cambridge NeuroScience. He was also a founder of TwistDx, a DNA diagnostics company acquired by Inverness Medical Innovations (now Alere, Inc.) in 2010. Dr. Mahanthappa received his Ph.D. in Neurobiology from the California Institute of Technology, and post-doctoral training at the E.K. Shriver Center for Mental Retardation (then affiliated with Massachusetts General Hospital) and Harvard Medical School. He received his MBA from the F.W. Olin Graduate School of Management at Babson College.
Amir Nashat, PhD
Managing General Partner, Polaris Venture Partners
Dr. Nashat is a partner based in the Boston office of Polaris, and focuses on investments in healthcare, consumer products and energy. Prior to joining Polaris, Dr. Nashat completed his PhD as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology with a minor in Biology under the guidance of Dr. Robert Langer. While at MIT, he also completed an internship in the London office of Goldman, Sachs & Company. Amir currently represents Polaris as a Director of aTyr Pharmaceuticals, BIND Biosciences, Fate Therapeutics, Promedior Pharmaceuticals, Receptos and Selecta Biosciences. Additionally, Dr. Nashat previously served as a Director of Adnexus Therapeutics (acquired by Bristol Myers Squibb), Athenix Corporation (acquired by Bayer), Avila Therapeutics (acquired by Celgene), Living Proof, Pervasis Therapeutics (acquired by Shire Pharmaceuticals), and served as a Board Observer of GI Dynamics (GID.AX). Dr. Nashat gained significant operational experience as the founding CEO of Living Proof, and Sun Catalytix Corporation. He currently serves on the Board of the New England Venture Capital Association, the Partners Innovation Fund and is a Catalyst of the Deshpande Center for Technological Innovation at MIT.
Timothy A. Springer, PhD
Co-founder, Scholar Rock®
Latham Family Professor at Harvard Medical School and Professor of Medicine at Children's Hospital Boston
Dr. Springer is an internationally recognized leader in structural biology and immunology. With over 500 peer-reviewed publications that have received over 90,000 citations, he is one of the most highly cited scientists in any field. Dr. Springer received his Ph.D. from Harvard University in 1976, and subsequent post-doctoral training with Dr. Cesar Milstein in Cambridge, UK. Dr. Springer has been elected to the National Academy of Sciences and to the American Academy of Arts and Sciences. Among numerous awards and honors, Dr. Springer is a recipient of the Royal Society of Medicine Medal, the William B. Coley Medal from the Cancer Research Institute, and the Crafoord Prize from the Swedish Academy of Sciences. Dr. Springer’s research laid the foundation for a new class of pharmaceuticals, the selective adhesion molecule inhibitors, which include the approved drugs, alefacept, efalizumab and natalizumab. Dr. Springer was the Founder of LeukoSite, a biotechnology company acquired by Millennium Pharmaceuticals in 1999. LeukoSite developed therapeutics for inflammatory, autoimmune, and cancer applications, including FDA-approved Campath™.
CONTACT  |  SITEMAP  | 
 |  SITE DESIGN
“Scholar Rock” is a registered trademark of Scholar Rock, Inc.  |  © 2017 Scholar Rock All Rights Reserved.
Back to Top
 

The site you are about to visit is maintained by another organization, which is solely responsible for its content. As we cannot control the content or privacy practices of any third-party websites, we encourage you to read the privacy policy of every website you visit.

Continue   Cancel